Read on Twitter
** Thread about new Lancet paper **
1/ How can we immunise the world against COVID-19?
We’ve tried to answer this in our paper in @TheLancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext
Ken Shadlen ( @LSE_ID) @MaxSalKo @ProfHeidiLarson @AJPollard1 Yot Teerawattananon ( @HITAP_Thailand) @MarkJit
1/ How can we immunise the world against COVID-19?
We’ve tried to answer this in our paper in @TheLancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext
Ken Shadlen ( @LSE_ID) @MaxSalKo @ProfHeidiLarson @AJPollard1 Yot Teerawattananon ( @HITAP_Thailand) @MarkJit
2/ Several firms have successfully developed new COVID-19 vaccines in under 12 months, a remarkable achievement.
Yet having new COVID-19 vaccines will mean little if people around the world are unable to get vaccinated in a timely manner.
Yet having new COVID-19 vaccines will mean little if people around the world are unable to get vaccinated in a timely manner.
3/ What’s needed are:
-Production at scale
-Affordable pricing
-Global allocation based on need
-Successful roll-out in local communities
We took deep dives—informed by current data—into each of these 4 dimensions of global vaccination.
-Production at scale
-Affordable pricing
-Global allocation based on need
-Successful roll-out in local communities
We took deep dives—informed by current data—into each of these 4 dimensions of global vaccination.
4/ To guide our review, we developed a dashboard to compare 26 leading vaccines on their potential contributions to achieving global vaccine immunity, using a traffic-light system.
5/ Production capacity is a key issue: few firms expect to produce more than 1bn doses in 2021—not enough to vaccinate the world population at once.
@WHO, @CEPI_vaccines, and @Gavi have urged companies to share knowledge, IP, and data on COVID-19 vaccines to expand production.
@WHO, @CEPI_vaccines, and @Gavi have urged companies to share knowledge, IP, and data on COVID-19 vaccines to expand production.
6/ With leading vaccine developers having received substantial funding (as much as $2.1bn) from governments and non-profit groups, funders could require that recipients engage in sufficient licensing and technology transfer to enable widespread global production.
7/ Funders can also ensure that vaccines are priced affordably. Some firms are setting prices for COVID-19 vaccines that are among the highest ever charged for a vaccine.
8/ As countries like the US, UK, UAE, and Israel forge ahead with their vaccination programmes, it’s important to remember that many poorer countries have yet to secure their supply, let alone begun administering jabs, even for front-line health workers and the most vulnerable.
9/ The widespread disregard for a global approach to vaccine allocation shown by national governments threatens to prolong the pandemic and increase the risk of new variants of the virus arising—against which existing vaccines may be less effective.
10/ We should take advantage of the many vaccines now available, as not all will be suitable for deployment universally. 1-dose vaccines which can be kept refrigerated, some of which are expected to be authorised soon, may prove to be game changers in resource-poor settings.
11/ We also need to increase public confidence and trust to improve uptake.
We present original data from a 32-country survey—involving almost 27,000 people—on potential acceptance of COVID-19 vaccines, conducted from October to December
We present original data from a 32-country survey—involving almost 27,000 people—on potential acceptance of COVID-19 vaccines, conducted from October to December
12/ The distinct characteristics of leading COVID-19 vaccines across the 4 dimensions of the global vaccination challenge generate trade-offs. Globally and nationally, the availability of diversified sets of vaccines is likely needed to bring the global pandemic under control.
13/ Here’s the table in our paper showing public and non-profit funding for the research, development, and production of leading vaccine candidates.
14/ Also take a look at the appendices which contain a wealth information about the data presented in the paper, including sources
Appendix 1 – https://www.thelancet.com/cms/10.1016/S0140-6736(21)00306-8/attachment/a8e7ad38-565f-4cba-8896-199efeac6a9a/mmc1.pdf
Appendix 2 – https://www.thelancet.com/cms/10.1016/S0140-6736(21)00306-8/attachment/35a44f38-3537-4aef-a644-ea47c9b5d06e/mmc2.pdf
Appendix 3 – https://www.thelancet.com/cms/10.1016/S0140-6736(21)00306-8/attachment/eae3d561-dc89-469b-9662-2eb7087f1b9d/mmc3.pdf
Appendix 1 – https://www.thelancet.com/cms/10.1016/S0140-6736(21)00306-8/attachment/a8e7ad38-565f-4cba-8896-199efeac6a9a/mmc1.pdf
Appendix 2 – https://www.thelancet.com/cms/10.1016/S0140-6736(21)00306-8/attachment/35a44f38-3537-4aef-a644-ea47c9b5d06e/mmc2.pdf
Appendix 3 – https://www.thelancet.com/cms/10.1016/S0140-6736(21)00306-8/attachment/eae3d561-dc89-469b-9662-2eb7087f1b9d/mmc3.pdf
